PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

por Mascarenhas, John, Harrison, Claire, Kiladjian, Jean-Jacques, Sockel, Katja, Vannucchi, Alessandro, Berry, Tymara, Redding, Denise, Sherman, Laurie, Dougherty, Souria, Peng, Lixian, Sun, Libo, Huang, Fei, Wan, Ying, Rodolf, Vivian, Ho, Judy, Navada, Shyamala, Komrokji, Rami S.
Publicado 2023